A new workshop for the production of biotechnological substances for women’s reproductive health has opened at Medsintez plant in Novouralsk, Sverdlovsk Region, according to the official website of the Plenipotentiary Representative of the President of the Russian Federation in the Ural Federal District.
Since 2018, the Medsintez plant and IVPharma have been successfully implementing a biotechnological project in reproductive technologies which involved the production of substances and ready-made dosage forms of Primapur, the first Russian drug for the treatment of infertility. The drug is included in the VED list and is successfully used in clinics throughout the country.
“Today we can safely say that one more important collaboration has been added to the medical cluster in the Middle Urals. The biotechnologies provided by Medsintez and IVPharma create a synergy with the expertise of Mother and Child clinics specialists. Thus, domestic medicines for women’s reproductive health are already available, and more are being developed,” Vladimir Yakushev, Plenipotentiary Envoy of the President of the Russian Federation said at the opening of the production line.
With the opening of a new workshop for the production of biotechnological substances, the plant now has the facilities to provide domestic medicine with modern, in-demand drugs. The production line can make up to 30 grams of FSH drug, or up to 1 million disposable pen injector devices per year. The Medsintez plant is ready to supply 200% of Russia’s annual demand for FSH drugs.
As a part of its import substitution activity, the company is conducting research and development work to prepare for the production of other hormonal drugs used in the IVF procedure. New medicinal preparations of human chorionic gonadotropin and gonadotropin-releasing hormone antagonist are currently at the stage of preliminary preparation before their submission for registration to the Ministry of Health of Russia.
